BetterLife Pharma Inc. (FRA:NPAU)
Germany
· Delayed Price · Currency is EUR 0.0330
+0.0050 (17.86%)
Last updated: Dec 5, 2025, 8:06 AM CET
BetterLife Pharma Income Statement
Financials in millions CAD. Fiscal year is February - January.
Millions CAD. Fiscal year is Feb - Jan.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 | Jan '21 Jan 31, 2021 | 2020 - 2016 |
| Cost of Revenue | - | - | - | - | - | 0.02 | Upgrade
|
| Gross Profit | - | - | - | - | - | -0.02 | Upgrade
|
| Selling, General & Admin | 2.27 | 4.3 | 2.64 | 6.56 | 4.53 | 7.56 | Upgrade
|
| Research & Development | 0.05 | 0.42 | 0.57 | 2.68 | 5.42 | 0.28 | Upgrade
|
| Operating Expenses | 2.33 | 4.72 | 3.21 | 9.26 | 9.97 | 7.93 | Upgrade
|
| Operating Income | -2.33 | -4.72 | -3.21 | -9.26 | -9.97 | -7.95 | Upgrade
|
| Interest Expense | -0.17 | -0.32 | -0.05 | -0.07 | -0.06 | -0.04 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.28 | -0.03 | -0.2 | -0.24 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.97 | 0.73 | -0.17 | -0 | -1.07 | -0.3 | Upgrade
|
| EBT Excluding Unusual Items | -1.54 | -4.59 | -3.46 | -9.53 | -11.33 | -8.25 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.19 | -15.86 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -12.12 | Upgrade
|
| Legal Settlements | 0.56 | 0.56 | 0.13 | 0.26 | -0.56 | -0.12 | Upgrade
|
| Other Unusual Items | 0.15 | 0.42 | 0.44 | -0.1 | -0.29 | - | Upgrade
|
| Pretax Income | -0.84 | -3.62 | -2.9 | -9.37 | -11.99 | -36.35 | Upgrade
|
| Income Tax Expense | - | - | - | - | 0.17 | - | Upgrade
|
| Earnings From Continuing Operations | -0.84 | -3.62 | -2.9 | -9.37 | -12.16 | -36.35 | Upgrade
|
| Minority Interest in Earnings | -0 | 0.1 | 0.01 | 0.36 | - | - | Upgrade
|
| Net Income | -0.84 | -3.52 | -2.89 | -9.02 | -12.16 | -36.35 | Upgrade
|
| Net Income to Common | -0.84 | -3.52 | -2.89 | -9.02 | -12.16 | -36.35 | Upgrade
|
| Shares Outstanding (Basic) | 135 | 124 | 109 | 87 | 75 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 135 | 124 | 109 | 87 | 75 | 27 | Upgrade
|
| Shares Change (YoY) | 16.13% | 13.34% | 26.25% | 14.70% | 179.24% | 79.75% | Upgrade
|
| EPS (Basic) | -0.01 | -0.03 | -0.03 | -0.10 | -0.16 | -1.34 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.03 | -0.03 | -0.10 | -0.16 | -1.34 | Upgrade
|
| Free Cash Flow | -0.35 | -2.02 | -2.47 | -1.5 | -11.2 | -7.18 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.02 | -0.02 | -0.02 | -0.15 | -0.27 | Upgrade
|
| EBITDA | - | - | -3.19 | -9.24 | -9.95 | -7.8 | Upgrade
|
| D&A For EBITDA | - | - | 0.02 | 0.02 | 0.02 | 0.16 | Upgrade
|
| EBIT | -2.33 | -4.72 | -3.21 | -9.26 | -9.97 | -7.95 | Upgrade
|
| Advertising Expenses | - | - | - | 0.12 | 0.44 | 0.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.